finance.yahoo.com ·
guggenheim lifts beone medicines onc 200026481
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article covers an analyst price target increase for BeOne Medicines AG, a biopharma company focused on cancer treatments. The commercial mechanism is a positive equity analyst revision based on strong Q1 revenue growth (35%) and margin expansion (89% gross margin). The impact is single-company-specific (BeOne Medicines/ONC) with no broader sector or supply chain disruption. The channel is a demand_spike for BRUKINSA and TEVIMBRA, improving revenue and gross margin. No scarcity or supply chain issues are mentioned.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Guggenheim analyst Michael Schmidt raised price target for BeOne Medicines AG (NASDAQ:ONC) from $410 to $420, maintaining Buy rating.
- Q1 total global revenue increased 35% to $1.5 billion.
- BRUKINSA (zanubrutinib) revenues reached $1.1 billion, up 38% year-over-year.
- Gross margin improved to 89% from 85% in the same period last year.
- Margin improvement attributed to higher sales mix of BRUKINSA and lower costs for BRUKINSA and TEVIMBRA.
BeOne Medicines (ONC) shares may see muted sentiment impact following analyst price target increase; expected impact is flat in the short term.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHshort
Related stories
finance.yahoo.com
ncmi q1 2026 earnings transcript 154748256
finance.yahoo.com
oncology institute q1 earnings call 050614985
economictimes.indiatimes.com
zydus lifesciences shares jump 6 on buyback buzz co announces 166 mn assertio acquisition
finance.yahoo.com
transcript valneva q1 2026 earnings 155143868
aol.com